TapewireFind a company

person · Reporting owner

Ford Alfred J Jr

Disclosed activity across 2 companies

Tapewire entity
25900
SEC CIK
0001359446

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Axonics, Inc.AXNX · Entity 86004Chief Commercial OfficerNovember 15, 2024November 15, 2024
KESTRA MEDICAL TECHNOLOGIES, LTD.KMTS · Entity 4686Chief Commercial OfficerAugust 04, 2026August 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Axonics, Inc.

Report date November 15, 2024 · Filed November 15, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-11-15 transaction · row 1
1 source row

Row 1 · 2024-11-15 · Disposition to issuer · Disposed 43,450 · Balance 0

F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration").

F2: The shares of the Issuer's common stock reported as disposed by the reporting person include restricted stock awards. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock award granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares subject to such restricted stock award, less applicable taxes and authorized deductions.

Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2024-11-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-11-15 · Disposition to issuer · Disposed 11,250 · Balance 0

F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of the Issuer's common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to be earned by the reporting person ranged from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total stockholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F4: Pursuant the Merge Agreement, at the Effective Time, each outstanding Performance-Based Restricted Stock Unit granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan for which the market condition is relative total stockholder return, whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares underlying such Performance-Based Restricted Stock Unit (based on the actual performance of the relevant peer group as of the Company's fiscal quarter-end immediately preceding the Effective Time and the Merger Consideration as the per share price), less applicable taxes and authorized deductions.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.82 · Expires 2029-12-12Direct0 Reported balance After 2024-11-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-11-15 · Disposition to issuer · Disposed 4,655 · Balance 0

F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration").

F2: The shares of the Issuer's common stock reported as disposed by the reporting person include restricted stock awards. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock award granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares subject to such restricted stock award, less applicable taxes and authorized deductions.

F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of the Issuer's common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to be earned by the reporting person ranged from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total stockholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F4: Pursuant the Merge Agreement, at the Effective Time, each outstanding Performance-Based Restricted Stock Unit granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan for which the market condition is relative total stockholder return, whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares underlying such Performance-Based Restricted Stock Unit (based on the actual performance of the relevant peer group as of the Company's fiscal quarter-end immediately preceding the Effective Time and the Merger Consideration as the per share price), less applicable taxes and authorized deductions.

F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

KESTRA MEDICAL TECHNOLOGIES, LTD.

Report date August 04, 2026 · Filed August 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect99,564 Reported balance After 2026-08-04 transaction · row 1
1 source row

Row 1 · 2026-08-04 · Sale · Disposed 6,275 · Balance 99,564

F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9000 to $24.5700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9000 to $24.5700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 04, 2026 Filed Aug 6, 2026 23:06 UTC KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 SaleCommon Shares 6,275 $24.09 $151,140.91
Disclosure

SEC source: 0001193125-26-338668 · ownership.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,564

F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9000 to $24.5700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 23:32 UTC KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 SaleCommon Shares 13,015 $23.90 $311,118.37
Disclosure

SEC source: 0001193125-26-331065 · ownership.xml · nonDerivative · entry 3

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,839

F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F4 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6600 to $24.2800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Read SEC document
July 31, 2026 Filed Aug 3, 2026 23:32 UTC KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 SaleCommon Shares 8,681 $22.61 $196,284.35
Disclosure

SEC source: 0001193125-26-331065 · ownership.xml · nonDerivative · entry 2

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,854

F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F3 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1700 to $22.9000. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Read SEC document
July 30, 2026 Filed Aug 3, 2026 23:32 UTC KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 SaleCommon Shares 5,936 $22.76 $135,120.57
Disclosure

SEC source: 0001193125-26-331065 · ownership.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,535

F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2696 to $23.2000. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Read SEC document
July 15, 2026 Filed Jul 17, 2026 21:51 UTC KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 GrantCommon Shares 58,832 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-308046 · ownership.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,471

F1 · shares: Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

Read SEC document
June 03, 2026 Filed Jun 4, 2026 22:39 UTC KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 GrantCommon Shares 25,227 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-257913 · ownership.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,639

F1 · shares: Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 21:09 UTC KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 GrantCommon Shares 29,412 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-097312 · ownership.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,412

F1 · shares: Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSU's will vest 9,804 on July 17, 2026, 9,804 on July 17, 2027 and 9,804 on July 17, 2028.

Read SEC document
March 07, 2025 Filed Sep 15, 2025 20:30 UTC Amendment KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 PurchaseCommon Shares 20,000 $17.00 $340,000.00
Disclosure

SEC source: 0001193125-25-203649 · ownership.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,412

F1 · shares: The reported securities were purchased in connection with the Issuer's initial public offering reserved share program and were inadvertently omitted from the Reporting Person's prior filings.

Read SEC document
November 15, 2024 Filed Nov 15, 2024 13:59 UTC Axonics, Inc. AXNX · Entity 86004 Disposition to issuerStock Option (Right to Buy) · Derivative 4,655 $45.18 Strike: $25.82 $210,312.90
Disclosure

SEC source: 0001562180-24-007704 · primarydocument.xml · derivative · entry 3

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,655 shares

Expires 2029-12-12

F5 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

Read SEC document
November 15, 2024 Filed Nov 15, 2024 13:59 UTC Axonics, Inc. AXNX · Entity 86004 Disposition to issuerPerformance-Based Restricted Stock Units · Derivative 11,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-007704 · primarydocument.xml · derivative · entry 2

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires not disclosed

F3 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of the Issuer's common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to be earned by the reporting person ranged from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total stockholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F3 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of the Issuer's common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to be earned by the reporting person ranged from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total stockholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F4 · kind: Pursuant the Merge Agreement, at the Effective Time, each outstanding Performance-Based Restricted Stock Unit granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan for which the market condition is relative total stockholder return, whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares underlying such Performance-Based Restricted Stock Unit (based on the actual performance of the relevant peer group as of the Company's fiscal quarter-end immediately preceding the Effective Time and the Merger Consideration as the per share price), less applicable taxes and authorized deductions.

F4 · derivative.exercise_date: Pursuant the Merge Agreement, at the Effective Time, each outstanding Performance-Based Restricted Stock Unit granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan for which the market condition is relative total stockholder return, whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares underlying such Performance-Based Restricted Stock Unit (based on the actual performance of the relevant peer group as of the Company's fiscal quarter-end immediately preceding the Effective Time and the Merger Consideration as the per share price), less applicable taxes and authorized deductions.

F3 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of the Issuer's common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to be earned by the reporting person ranged from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total stockholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F4 · derivative.expiration_date: Pursuant the Merge Agreement, at the Effective Time, each outstanding Performance-Based Restricted Stock Unit granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan for which the market condition is relative total stockholder return, whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares underlying such Performance-Based Restricted Stock Unit (based on the actual performance of the relevant peer group as of the Company's fiscal quarter-end immediately preceding the Effective Time and the Merger Consideration as the per share price), less applicable taxes and authorized deductions.

Read SEC document
November 15, 2024 Filed Nov 15, 2024 13:59 UTC Axonics, Inc. AXNX · Entity 86004 Disposition to issuerCommon Stock 43,450 $71.00 $3,084,950.00
Disclosure

SEC source: 0001562180-24-007704 · primarydocument.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration").

F2 · kind: The shares of the Issuer's common stock reported as disposed by the reporting person include restricted stock awards. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock award granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares subject to such restricted stock award, less applicable taxes and authorized deductions.

F1 · price: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration").

Read SEC document
January 31, 2024 Filed Feb 2, 2024 22:59 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 15,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-001011 · primarydocument.xml · derivative · entry 4

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

F4 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

F4 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 22:59 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 10,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-001011 · primarydocument.xml · derivative · entry 3

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024.

F3 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024.

F3 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 22:59 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 16,615 $67.74 $1,125,431.98
Disclosure

SEC source: 0001562180-24-001011 · primarydocument.xml · nonDerivative · entry 2

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,450

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the vesting of Performance-Based Restricted Stock Units disclosed herein and the vesting of Restricted Stock Awards.

F2 · price: This transaction was executed in multiple trades at prices ranging from $67.53 to $68.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 22:59 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 25,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-001011 · primarydocument.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 23:47 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 14,769 $62.34 $920,671.40
Disclosure

SEC source: 0001562180-23-006422 · primarydocument.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,565

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan entered into on March 17, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 28, 2023 Filed Aug 2, 2023 00:01 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 1,500 $62.01 $93,021.00
Disclosure

SEC source: 0001562180-23-006100 · primarydocument.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,334

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan entered into on March 17, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 3,164 $61.02 $193,054.62
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · nonDerivative · entry 6

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,834

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F5 · price: This transaction was executed in multiple trades at prices ranging from $60.85 to $61.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 541 $60.43 $32,695.17
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · nonDerivative · entry 5

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,998

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F4 · price: This transaction was executed in multiple trades at prices ranging from $59.85 to $60.845. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 11,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · derivative · entry 10

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

F9 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

F9 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 5,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · derivative · entry 9

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

F8 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

F8 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 7,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · derivative · entry 8

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires not disclosed

F7 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F7 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F7 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 15,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · derivative · entry 7

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F6 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

F6 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

F6 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 1,999 $61.12 $122,182.68
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · nonDerivative · entry 4

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,539

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F3 · price: This transaction was executed in multiple trades at prices ranging from $60.78 to $61.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 4,235 $61.17 $259,052.41
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · nonDerivative · entry 3

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,538

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2 · price: This transaction was executed in multiple trades at prices ranging from $60.78 to $61.595. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 16,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · nonDerivative · entry 2

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 31, 2023 Filed Feb 3, 2023 01:07 UTC Axonics, Inc. AXNX · Entity 86004 GrantCommon Stock 7,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000875 · primarydocument.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,273

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 8,509 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · derivative · entry 11

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,509 shares

Expires 2027-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on November 15, 2017 and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of November 15, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 1,899 $0.00 Strike: $1.63 $0.00
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · derivative · entry 10

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,899 shares

Expires 2028-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018 and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 16,297 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · derivative · entry 9

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,297 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 9,310 $0.00 Strike: $25.82 $0.00
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · derivative · entry 8

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,655

Underlying: Common Stock · 9,310 shares

Expires 2029-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 12, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 3,615 $67.18 $242,840.88
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · nonDerivative · entry 7

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,773

F3 · price: This transaction was executed in multiple trades at prices ranging from $67.13 USD to $67.215 USD; the price reported above reflects the weighted average sale price.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 17,108 $66.69 $1,140,874.35
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · nonDerivative · entry 6

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,388

F2 · price: This transaction was executed in multiple trades at prices ranging from $66.085 USD to $67.08 USD; the price reported above reflects the weighted average sale price.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 15,292 $65.90 $1,007,699.98
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · nonDerivative · entry 5

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,496

F1 · price: This transaction was executed in multiple trades at prices ranging from $65.05 USD to $66.04 USD; the price reported above reflects the weighted average sale price.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 16,297 $14.19 $231,254.43
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · nonDerivative · entry 4

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 9,310 $25.82 $240,384.20
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · nonDerivative · entry 3

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 1,899 $1.63 $3,095.37
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · nonDerivative · entry 2

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 13, 2023 Filed Jan 19, 2023 01:03 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 8,509 $1.42 $12,082.78
Disclosure

SEC source: 0001562180-23-000494 · primarydocument.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 03, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 14,130 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · derivative · entry 8

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,130 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021.

F7 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021.

F7 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021.

Read SEC document
February 03, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 10,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · derivative · entry 7

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022.

F6 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022.

F6 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022.

Read SEC document
February 03, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 470 $49.03 $23,046.31
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · nonDerivative · entry 4

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,773

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F3 · price: This transaction was executed in multiple trades at prices ranging from $48.78 to $49.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 03, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 8,797 $48.21 $424,106.01
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · nonDerivative · entry 3

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,243

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2 · price: This transaction was executed in multiple trades at prices ranging from $47.76 to $48.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 03, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 24,130 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · nonDerivative · entry 2

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,040

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 31, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 5,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · derivative · entry 6

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires not disclosed

F5 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024.

F5 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024.

F5 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024.

Read SEC document
January 31, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 5,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · derivative · entry 5

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires not disclosed

F4 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

F4 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

F4 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

Read SEC document
January 31, 2022 Filed Feb 4, 2022 02:31 UTC Axonics, Inc. AXNX · Entity 86004 GrantCommon Stock 16,285 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001106 · primarydocument.xml · nonDerivative · entry 1

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,910

Read SEC document
April 19, 2021 Filed Apr 22, 2021 01:19 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 14,871 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001562180-21-002904 · primarydocument.xml · derivative · entry 10

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,509

Underlying: Common Stock · 14,871 shares

Expires 2027-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on November 15, 2017 and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of November 15, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
April 19, 2021 Filed Apr 22, 2021 01:19 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 5,721 $0.00 Strike: $1.63 $0.00
Disclosure

SEC source: 0001562180-21-002904 · primarydocument.xml · derivative · entry 9

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,899

Underlying: Common Stock · 5,721 shares

Expires 2028-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018 and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
April 19, 2021 Filed Apr 22, 2021 01:19 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 19,258 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001562180-21-002904 · primarydocument.xml · derivative · entry 8

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,297

Underlying: Common Stock · 19,258 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
April 19, 2021 Filed Apr 22, 2021 01:19 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 6,347 $0.00 Strike: $25.82 $0.00
Disclosure

SEC source: 0001562180-21-002904 · primarydocument.xml · derivative · entry 7

Ford Alfred J Jr · CIK 0001359446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,965

Underlying: Common Stock · 6,347 shares

Expires 2029-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 12, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.